Published in Blood on June 01, 2001
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood (2010) 2.17
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med (2013) 1.69
Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest (2008) 1.57
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant (2013) 1.51
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 1.42
Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 1.38
VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One (2017) 1.38
Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int (2007) 1.34
Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.26
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood (2003) 1.25
Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. Haematologica (2010) 1.23
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica (2010) 1.19
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant (2013) 1.09
Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant (2008) 1.05
Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. J Clin Immunol (2011) 1.03
Human dendritic cells following Aspergillus fumigatus infection express the CCR7 receptor and a differential pattern of interleukin-12 (IL-12), IL-23, and IL-27 cytokines, which lead to a Th1 response. Infect Immun (2006) 1.02
Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy (2012) 1.01
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol (2004) 0.99
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biol Blood Marrow Transplant (2009) 0.97
Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol (2005) 0.95
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. Biol Blood Marrow Transplant (2011) 0.95
The immunopathology of thymic GVHD. Semin Immunopathol (2008) 0.94
Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. J Hematol Oncol (2013) 0.94
Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther (2008) 0.93
Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. BMC Immunol (2009) 0.92
Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer (2012) 0.91
T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naive T cells. Haematologica (2013) 0.89
The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus (2012) 0.88
Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation. J Transl Med (2013) 0.88
T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology (2002) 0.87
Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid Med Cell Longev (2010) 0.86
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant (2012) 0.84
Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence (2016) 0.83
Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation. Adv Hematol (2015) 0.82
The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood (2017) 0.80
Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica (2014) 0.79
Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. Haematologica (2016) 0.78
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2016) 0.78
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant (2008) 0.77
Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation. J Immunol Res (2014) 0.77
CD154-CD40 interactions in the control of murine B cell hematopoiesis. J Leukoc Biol (2011) 0.77
Clinical factors influencing phenotype of HCMV-specific CD8+ T cells and HCMV-induced interferon-gamma production after allogeneic stem cells transplantation. Clin Dev Immunol (2013) 0.76
KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT). Hum Immunol (2012) 0.75
Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes. Bone Marrow Transplant (2014) 0.75
Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis (2016) 0.75
Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications. Stem Cell Investig (2017) 0.75
Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget (2017) 0.75
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
The repair of double-strand breaks in the nuclear DNA of Saccharomyces cerevisiae and its genetic control. Mol Gen Genet (1976) 6.89
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
Nucleotide sequence of the tetM tetracycline resistance determinant of the streptococcal conjugative shuttle transposon Tn1545. Nucleic Acids Res (1986) 4.47
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science (1982) 4.07
Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med (2001) 3.98
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med (1989) 3.45
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry (1995) 3.30
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18
Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell (2001) 3.05
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95
Dynamic actin-based epithelial adhesion and cell matching during Drosophila dorsal closure. Curr Biol (2000) 2.78
The canine major histocompatibility complex. Supertypic specificities defined by the primed lymphocyte test (PLT). Immunogenetics (1984) 2.72
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med (1990) 2.66
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Mechanisms of epithelial fusion and repair. Nat Cell Biol (2001) 2.63
Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis (1998) 2.61
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation (1997) 2.58
Failure of silicone gel breast implants: analysis of literature data for 1652 explanted prostheses. Plast Reconstr Surg (1997) 2.56
Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon. EMBO J (1984) 2.55
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52
Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol (1997) 2.49
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther (2013) 2.38
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature (1995) 2.33
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24
Safeguards for research using large scale DNA collections. BMJ (2000) 2.22
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
An immunohistochemical method that differentiates Cryptococcus neoformans varieties and serotypes in formalin-fixed paraffin-embedded tissues. Med Mycol (2001) 2.16
Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat (2013) 2.15
Putting ion channels to work: mechanoelectrical transduction, adaptation, and amplification by hair cells. Proc Natl Acad Sci U S A (2000) 2.15
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene. Science (1984) 2.12
Healing of incisional wounds in the embryonic chick wing bud: characterization of the actin purse-string and demonstration of a requirement for Rho activation. J Cell Biol (1996) 2.12
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg (1995) 2.03
Hypodontia due to ectodermal dysplasia: rehabilitation with very early dental implants. Rev Stomatol Chir Maxillofac Chir Orale (2013) 1.97
[Hypodontia due to ectodermal dysplasia: rehabilitation with very early dental implants]. Rev Stomatol Chir Maxillofac Chir Orale (2013) 1.97
Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood (2001) 1.92
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92